Exchange: NASDAQ·Updated 04:31 AM EDT
CRIS logo

CRIS Curis Inc

$0.829
$0.0256
(3.19%)
Pre-Market
Prev Close $0.8034
EarningsNov 5
Mkt Cap$1.68M
Vol143,369.00

About CRIS

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
43

Bearish Sentiment

How do you feel about CRIS?

Advertisement|Remove ads.